Investors & Media

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of product candidates to treat patients suffering from central nervous system diseases. Minerva is developing roluperidone for the treatment of negative symptoms in patients with schizophrenia and has exclusive rights to develop MIN-301 for the treatment of Parkinson’s disease. Minerva co-developed seltorexant with Janssen Pharmaceutica NV for the treatment of insomnia disorder and adjunctive treatment of Major Depressive Disorder. Janssen is currently conducting Phase 3 trials with seltorexant.


Minerva has not received any regulatory approvals to commercialize its product candidates and has not generated any revenue from the sales or license of any product candidates. Minerva has incurred significant operating losses since inception and expects to continue to incur net losses and negative cash flows from operating activities for the foreseeable future in connection with clinical and regulatory activities. Minerva’s common stock is listed on Nasdaq under the symbol “NERV”.

Minerva is committed to providing investors access to current and historical information about the Company, including news regarding product development programs, key shareholder updates and financial reports.